AstraZeneca PLC (AZN)vsRigel Pharmaceuticals Inc (RIGL)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
RIGL
Rigel Pharmaceuticals Inc
$29.22
-4.38%
HEALTHCARE · Cap: $564.75M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 19860% more annual revenue ($58.74B vs $294.28M). RIGL leads profitability with a 124.7% profit margin vs 17.4%. RIGL trades at a lower P/E of 1.6x. RIGL earns a higher WallStSmart Score of 79/100 (B+).
AZN
Buy64
out of 100
Grade: C+
RIGL
Strong Buy79
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+88.2%
Fair Value
$294.92
Current Price
$29.22
$265.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 186 in profit
Keeps 125 of every $100 in revenue as profit
Strong operational efficiency at 33.2%
Earnings expanding 1599.0% YoY
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : RIGL
The strongest argument for RIGL centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 124.7% and operating margin at 33.2%. Revenue growth of 21.2% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : RIGL
The primary concerns for RIGL are Market Cap.
Key Dynamics to Monitor
AZN profiles as a value stock while RIGL is a growth play — different risk/reward profiles.
RIGL carries more volatility with a beta of 1.27 — expect wider price swings.
RIGL is growing revenue faster at 21.2% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
RIGL scores higher overall (79/100 vs 64/100), backed by strong 124.7% margins and 21.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Rigel Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?